Institutional investors boost stakes in Solventum, amid mixed analyst ratings and a consensus "Hold."

MetLife Investment Management and several other institutional investors increased their stakes in Solventum Co., a healthcare company with four business segments. Mizuho initiated coverage with a neutral rating and a $70 price target, while other firms have varied ratings and targets, leading to a consensus "Hold" with a $68.29 target price. Solventum's stock ranges between a 1-year low of $47.16 and a high of $96.05.

4 months ago
5 Articles